Search results for "Glycaemic Control"

showing 3 items of 13 documents

DETERMINATION OF MAXIMAL FAT OXIDATION FOR PRESCRIBING EXERCISE IN SEDENTARY NON-OBESE TYPE 2 DIABETES SUBJECTS

2014

Aim: To determine the exercise intensity that elicits the highest fat oxidation rate in sedentary non-obese subjects with type 2 diabetes. Methods: Eleven sedentary subjects with type 2 diabetes (T2DS) and eleven healthy sedentary subjects (HS), aged 45 to 65 and non-obese, were evaluated to a graded exercise test. Oxygen uptake (VO2) and fat oxidation rate (FAT) were detected. FAT was then plotted as a function of exercise intensity, expressed as percentage of VO2max. We determined the exercise intensity (%VO2max) at which fat oxidation was maximal (FATmax). Results: Absolute FATmax was not significantly different between T2DS and HS (0.51  0.13 vs. 0.56  0.29 g∙min-1). FATmax occurred a…

MetabolismPhysical activityGlycaemic controlGlycemic indexMotor activitySettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorie
researchProduct

Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐…

2020

Abstract Aim To assess the impact of the timing of initiating both basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (T2D) uncontrolled on oral antihyperglycaemic drugs with an HbA1c of 9% or higher. Methods This retrospective cohort study assessed the impact of the timing of initiating both basal insulin and GLP‐1 RA therapies on reaching glycaemic targets (HbA1c < 7% and <8%, and ≥1% and ≥2% HbA1c reduction) over 12 months in people with markedly uncontrolled T2D (HbA1c ≥ 9%) on oral antihyperglycaemic drugs identified on the Optum Humedica database (electronic medical records; …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismInsulins030209 endocrinology & metabolismGlycemic ControlType 2 diabetes030204 cardiovascular system & hematologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyGLP‐1 analogueInternal medicinecohort studyInternal MedicineHumansHypoglycemic AgentsInsulinMedicinebasal insulinRetrospective StudiesGlycated Hemoglobindatabase researchbusiness.industryMedical recordHazard ratioRetrospective cohort studyOriginal Articlesmedicine.diseaseGlucagon-like peptide-1Confidence intervalglycaemic controlDiabetes Mellitus Type 2Pharmaceutical PreparationsCohortOriginal Articletype 2 diabetesbusinessCohort studyDiabetes, Obesity and Metabolism
researchProduct

Associations between type of treatment and illness-specific locus of control in type 1 diabetes patients

1993

Abstract This study examined differences in diabetes-specific locus of control beliefs of 82 insulin-treated Type I diabetes patients undergoing either conventional therapy (CT), intensified conventional therapy (ICT) or continuous subcutaneous insulin infusion (CSII). Compared to CT with its adherence to a strict regimen, ICT and CSII allow a much greater flexibility in timing of meals and daily activities. On the other hand, such flexibility requires a much more active role of the patient. The hypotheses of higher internality and lower powerful others locus of control beliefs in ICT and CSII patients than in CT patients could be supported for powerful others locus of control only. A one-y…

medicine.medical_specialtyType 1 diabetesActivities of daily livingbusiness.industrymedia_common.quotation_subjectPublic Health Environmental and Occupational HealthFlexibility (personality)General MedicineGeneral Chemistrymedicine.diseaseSurgerySubcutaneous insulinRegimenLocus of controlInternal medicinemedicinePersonalityPoor glycaemic controlbusinessApplied Psychologymedia_commonPsychology &amp; Health
researchProduct